PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer

The phase 2b REZILIENT1 trial of zipalertinib in EGFR+ non–small cell lung cancer met its overall response rate primary end point with a consistent safety profile.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Pending phase 3 trial results, a biologics license application will be submitted for the KRAS-targeting cancer vaccine ELI-002.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training to use AI effectively.